# TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)

> **NCT03247309** · PHASE1 · COMPLETED · sponsor: **Immatics US, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Solid Tumor
- Cancer
- Recurrent Solid Tumors
- Refractory Solid Tumors

## Interventions

- **BIOLOGICAL:** IMA201 Product
- **DIAGNOSTIC_TEST:** IMADetect®

## Key facts

- **NCT ID:** NCT03247309
- **Lead sponsor:** Immatics US, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-19
- **Primary completion:** 2023-04-20
- **Final completion:** 2023-09-18
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03247309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03247309, "TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03247309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*